FDA has approved the first treatment to redesign immune system so it attacks the cancer cells. Kymriah therapy, which leaves 83% of people free of a type of blood cancer, costs about $475,000 and was developed by Novartis. The “living drug” is tailor-made to each patient, unlike conventional therapies such as surgery or chemotherapy. It is called CAR-T and is made by extracting white blood cells from the blood. Out of 63 patients treated with CAR-T therapy, 83% were in complete remission within three months.

Read More